Nona Biosciences and OverT Bio have joined forces to develop cutting-edge cell therapies for solid tumors. This strategic collaboration leverages Nona’s fully human HCAb technology and OverT Bio’s innovative genetic enhancements, aiming to deliver transformative therapies for patients.
Aadi Bioscience has decided to stop its PRECISION1 trial for nab-sirolimus in patients with solid tumors due to insufficient efficacy for accelerated approval. The company is prioritizing cash preservation, focusing on its marketed product Fyarro and continuing two ongoing Phase 2 trials. To further conserve resources, Aadi will reduce its R&D workforce by 80%.
Centessa Pharmaceuticals is poised for significant progress in 2024, with several promising clinical programs advancing towards key milestones. The company’s lead candidate, SerpinPC, is being evaluated in two pivotal trials for the treatment of Hemophilia B, targeting both patients with and without inhibitors. Positive interim results from the PRESent-2 study are expected in 2024, which could provide a major catalyst for the stock price. Additionally, Centessa is developing ORX750 for Narcolepsy Type 1 and LB101, a tetravalent bi-specific monoclonal antibody for solid tumors, with initial data expected for both programs later this year. With a strong pipeline and a solid financial position, Centessa Pharmaceuticals presents an attractive investment opportunity for investors seeking potential gains.
